BioNTech SE
BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancersā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$111.30
Price-0.09%
-$0.10
1Y
Price
Market Cap
$26.756b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-133.5%
EBITDA Margin-148.2%
Net Profit Margin+44.6%
Free Cash Flow MarginRevenue
$2.862b
+4.0%
1y CAGR-34.0%
3y CAGR-27.7%
5y CAGREarnings
-$347.445m
+47.8%
1y CAGR-71.3%
3y CAGR-55.5%
5y CAGREPS
-$1.44
+48.0%
1y CAGR-71.3%
3y CAGR-56.0%
5y CAGRBook Value
$18.505b
$21.638b
Assets$3.133b
Liabilities$269.600m
DebtDebt to Assets
1.3%
-6.5x
Debt to EBITDAFree Cash Flow
-$2.559b
-946.1%
1y CAGR-372.0%
3y CAGR+145.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company